PDS Biotechnology selected to collaborate on nanotechnology cancer therapies
PDS Biotechnology Corporation has announced that it has been selected as a collaborator of the U.S. National Cancer Institute’s Nanotechnology Characterization Lab (NCL) to complete preclinical trials of Versamune-HPV.Versamune-HPV is an immunotherapy drug which has shown promise in curing HPV infection and HPV-related cancer in preclinical animal and human model studies.The drug works by facilitating the uptake of disease-associated protein and peptide antigens while simultaneously acting as a strong immune system activator, without the inflammatory side effects caused by other activators.NCL will perform studies on PDS’s behalf at its facilities in Frederick, Maryland.Read the full release here.
PDS Biotechnology Corporation has announced that it has been selected as a collaborator of the U.S. National Cancer Institute’s Nanotechnology Characterization Lab (NCL) to complete preclinical trials of Versamune-HPV.
Versamune-HPV is an immunotherapy drug which has shown promise in curing HPV infection and HPV-related cancer in preclinical animal and human model studies.
The drug works by facilitating the uptake of disease-associated protein and peptide antigens while simultaneously acting as a strong immune system activator, without the inflammatory side effects caused by other activators.
NCL will perform studies on PDS’s behalf at its facilities in Frederick, Maryland.
Read the full release here.
Author
